cerrar
Tagged with strategy

Bradley Campbell – President & COO, Amicus…
Brad Campbell, president and COO of US rare disease specialist Amicus, talks domestic and global product launches, the company’s first steps into…

Tytus Litynski – General Manager Switzerland & Member…
Alfasigma Switzerland’s Dr Tytus Litynski introduces the Italian firm’s diversified portfolio of both Rx drugs and food supplements in…

Hilde Bech – General Manager, BMS Norway
BMS Norway’s Hilde Bech outlines her hopes of bringing "the medicines of the future" to Norwegian patients, why tiny Norway still has global…

Katharina Gasser – Managing Director, Biogen Switzerland…
Biogen Switzerland’s Dr Katharina Gasser outlines how the company’s 100 percent commitment to neuroscience helps it to stand apart, why…

Gary Zieziula – President & Region Head North America,…
Gary Zieziula, president & region head North America for Kyowa Kirin, a specialty care-focused Japan-based global pharma company, highlights the…

Philipp Maerz – Head of Northern Cluster & GM Norway,…
Philipp Maerz, the recently appointed head of Merck’s Nordic and Baltic operations and GM for Norway, outlines the challenges of taking on a new…

Axel Steiger – CEO, Bayer Switzerland
Axel Steiger, CEO and CFO for Bayer Switzerland, outlines the importance of the Swiss operations as one of the key global hubs for Bayer, his…

Chinese Biotech Strategies: Biologics or Small Molecules
While the vast majority of the global pharma market still comprises small molecule drugs, the biologics sector has grown rapidly since its inception…

Chinese Biotech Strategies: The Pros & Cons of In-Licensing
Since the Chinese biopharma boom started in the late-2000s, Chinese biotechs have seen in-licensing as a shortcut to establishing their own portfolios…

US Biotech Commercialisation Strategies: How Karyopharm &…
With US still the reigning global champion in biotech innovation, the dynamic and vibrant biopharma ecosystem in the world’s largest healthcare…

How Chugai Became Japan’s Top Pharma Company
In 2020, Chugai Pharmaceutical Co. became Japan’s biggest drug company, driven by strong performance in recent years both from the company’s own…

Thomas Willemsen – SVP APAC, Takeda
In an exclusive and wide-ranging interview, Takeda APAC SVP Thomas Willemsen outlines his strategy for bringing the company’s specialty pharma…
We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here